(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-1.31%) $82.75
(6.40%) $2.05
(0.03%) $2 347.90
(-0.22%) $27.48
(3.93%) $958.35
(-0.22%) $0.933
(-0.34%) $10.99
(-0.56%) $0.796
(1.66%) $93.40
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases...
Stats | |
---|---|
Today's Volume | 81 609.00 |
Average Volume | 680 403 |
Market Cap | 17.46M |
EPS | $-10.19 ( 2024-04-03 ) |
Next earnings date | ( $-1.180 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.150 |
ATR14 | $0.121 (0.72%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-28 | Truex Samantha | Buy | 0 | |
2024-03-27 | Goldman Jonathan | Buy | 0 | |
2024-03-28 | Kantoff Aaron | Buy | 0 | |
2023-12-20 | Persson Magnus | Buy | 3 334 | Stock Option (Right to Buy) |
2023-12-20 | Almenoff June Sherie | Buy | 3 334 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-62.67 |
Last 97 transactions |
Buy: 5 555 925 | Sell: 5 291 542 |
Volume Correlation
Avalo Therapeutics, Inc. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Avalo Therapeutics, Inc. Correlation - Currency/Commodity
Avalo Therapeutics, Inc. Financials
Annual | 2023 |
Revenue: | $1.92M |
Gross Profit: | $640 000 (33.26 %) |
EPS: | $-113.58 |
FY | 2023 |
Revenue: | $1.92M |
Gross Profit: | $640 000 (33.26 %) |
EPS: | $-113.58 |
FY | 2022 |
Revenue: | $18.05M |
Gross Profit: | $14.62M (80.98 %) |
EPS: | $-1 062.68 |
FY | 2021 |
Revenue: | $5.40M |
Gross Profit: | $3.91M (72.38 %) |
EPS: | $-9.96 |
Financial Reports:
No articles found.
Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators